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SuMMarY
Epidemiological studies conducted in Peru disclosed HTLV-1 to be prevalent in different ethnic groups, and found HTLV-2 in 
some Amazonian Indians and in men who have sex with men. No data concerning HTLV-1/2 infection in blood donors from Arequipa, 
a highlands region in southern Peru, is available. We searched for the presence of HTLV-1 and HTLV-2 antibodies in 2,732 serum 
samples obtained from blood donors from this geographic area. HTLV-1/2-specific antibodies were detected using an enzyme-linked 
immunosorbent assay (ELISA) and were confirmed by Western blot (WB). Reactive sera had their blood bags discarded from donation, 
and the demographic characteristics of the donors were analyzed. Thirty-five sera (1.2%) were HTLV seroreactive by ELISA, and 
25 were confirmed HTLV-1-positive by WB. One serum disclosed HTLV-positivity, and the remaining nine serum samples showed 
indeterminate results by WB; three of which had an HTLV-1 indeterminate Gag profile. The median age of HTLV-positive individuals 
was 34.6 years; 27 were male and eight were female. All individuals were from southern Peru: 27 from Arequipa, five from Puno, 
and three from Cuzco. HTLV co-positivity with hepatitis B (five sera) and syphilis (one serum) were detected. Previous transfusion 
and tattooing were observed in two and one individuals, respectively. No serum was positive for HTLV/HIV co-infection. This study 
confirmed, for the first time, HTLV-1 infection and the absence of HTLV-2 infection in blood donors from Arequipa, Peru and suggests 
vertical transmission as the major route of HTLV-1 transmission and acquisition in this geographic region. 
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iNtroduCtioN
In June 1998, the Ministry of Health of Peru required mandatory 
serology screening for HTLV-1/2 in blood centers and recommended to 
discard blood bags positive for such diseases/pathogens20. Antibodies to 
HTLV-1/2 have been screened by agglutination tests and enzyme-linked 
immunosorbent assays (ELISA). Confirmatory and discriminatory tests 
were immunofluorescence assay (IFA) and Western Blot (WB), but these 
were not compulsory for blood banks in Peru. 
Several epidemiological studies on HTLV-1/2 infection have been 
conducted in Peru, but the majority of them are related to high-risk or 
at-risk populations, such as HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) patients, men who have sex with men 
(MSM), patients with sexually transmitted diseases (STDs), and female 
sex workers (FSW)8,9,11,26,28,29. 
HTLV-1 is endemic in several Peruvian populations. Among healthy 
women, a study conducted in three Peruvian regions disclosed HTLV-1 rates 
of 1.3% in Huanta (an Andean city inhabited by indigenous Quechuas), 
3.8% in El Carmen (an African-American coastal town), and 3.8% in Lima 
(a city of Mestizo population in Peru)24. In pregnant women throughout 
Peru, 1.7% were infected with HTLV-1. Among them, seroprevalence 
increased with age but did not vary by region of birth1. HTLV-1 infection 
is also frequent in the offspring of Peruvian HTLV-1-infected women, 
showing frequencies of 6% among children from asymptomatic mothers, 
19% in children whose mother has HAM/TSP, and 31% among offspring 
of mothers with strongyloidiasis10. An epidemiological study conducted 
among at-risk individuals from Cuzco and Quillabamba, both in southern 
Peru, suggested that HTLV-1 is endemic in this region29.
Curiously, HTLV-1 is also endemic among Amerindians in Peru, a 
population thought to be infected with HTLV-2 in several countries of 
Latin America7,13,19,22. Nevertheless, HTLV-2 was only detected in two 
Peruvian Amazonian Indians and in several MSM from Peru19,28.
Little is known about HTLV-1/2 infection in blood-transfused 
patients and in blood donors from Peru12,17. Thus, the present study 
aimed to add information concerning blood donors from Arequipa, a 
city located in a highlands region of southern Peru whose population 
has Mestizo (Spanish-Indian) origin. We searched for the presence of 
HTLV-1- and HTLV-2-specific antibodies and tried to identify modes 
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of virus transmission/acquisition by analyzing demographic risk factors 
obtained from a blood donation questionnaire. 
MaterialS aNd MethodS
Study population: During 2005, all blood donors from Hospital 
Goyeneche and Hospital Honorio Delgado Espinoza, Arequipa, Peru (n = 
2,732) had their blood screened for the presence of six blood transmitted 
diseases (HIV, HTLV-1/2, HBV, HCV, Chagas disease, and syphilis). 
Serum samples were analyzed for the presence of specific antibodies 
to HTLV-1/2 using an ELISA kit that employs HTLV-1/2 viral lysates 
plus recombinant proteins from HTLV-1/2 as antigens (Vironostika 
HTLV-I/II, Organon Teknika, Durhan, DC). The reactions were conducted 
according to manufacturer instructions. Sera that produced OD/cutoff 
≥1.0 were considered reactive for HTLV-1/2 antibodies and excluded 
from blood donation. 
Additionally, HTLV-1/2-positive sera were sent to Instituto Adolfo 
Lutz (IAL), a public heath laboratory of São Paulo, Brazil, for confirming 
and discriminating HTLV-1- from HTLV-2-seropositive samples. The 
algorithm tests used by IAL for HTLV-1/2 diagnosis employ two 
ELISAs of different formats and compounds as screening, and WB as 
a confirmatory assay16. The kits used for screening were Vironostika 
HTLV-I/II (BioMerieux, France) and BioELISA HTLV-I+II (r) (BioKit 
S.A., Spain), and for confirmatory test, WB 2.4 (Genelabs Diagnostics, 
Singapore). The reactions were conducted according to manufacturers’ 
instructions. WB results were stringently evaluated, with HTLV-1 
positivity defined as reactivity to Gag (p19 with or without p24) and 
two Env (GD21 and rgp46-I) bands, and HTLV-2 positivity defined as 
reactivity to Gag (p24 with or without p19) and two Env (GD21 and 
rgp46-II) bands. Reactivity to Gag (p19 and p24) and Env (GD21) denoted 
HTLV positivity. Reactivity to Gag (p19 and p24) and Env (GD21, 
rgp46-I and rgp46-II) bands defined HTLV-1 and HTLV-2 seropositivity. 
Any other pattern of bands was considered indeterminate. 
The HTLV-1/2-positive results were analyzed in relation to 
demographic characteristics of blood donors obtained from a 
questionnaire which included age, gender, local of origin and residence, 
and factors for infection (e.g., previous blood transfusion, history of 
acupuncture, previous surgery, hepatitis, tattooing, intravenous drug use 
(IDU), and genital ulcer). In addition, sexual behaviors-history of STDs, 
sexual contact with sex workers, number of partners in the last three 
years, homosexual contact, use of condom during sexual intercourse, 
and others - were evaluated.
The study was approved by the Ethics Committees of Institutions, 
and by the Dirección Regional de Salud, Arequipa, Peru. 
reSultS
Out of 2,732 blood samples, 35 (1.2%) resulted HTLV-1/2-positive in 
screening tests conducted in Peru and were sent to IAL for confirmatory 
analyses. All sera confirmed HTLV-1/2-reactivity on the HTLV-I/II 
Vironostika ELISA kit, but six out of 35 sera were non-reactive on the 
Biokit ELISA test (Table 1). Figure 1 presents the results obtained on 
WB 2.4 analyses, showing HTLV-1 seropositivity in the majority of 
samples (25 out of 35 sera) and the absence of HTLV-2-positive serum. 
In addition, WB disclosed one HTLV-positive sample (lane 34), and nine 
indeterminate sera. Among them, HTLV-1 Gag indeterminate profile 
(HGIP), defined as the presence of p19, p26, p28, p32 and p36 without 
p24 or env gp21 and gp46, was detected in three serum samples (lanes 
12, 19, and 32). One serum presented a pattern suggestive of HTLV-1 but 
with no GD21 (lane 11). Curiously, all samples that were negative on the 
Biokit ELISA test were indeterminate by WB (Table 1 and Fig. 1).
The major demographic characteristics of HTLV-1/2-positive 
individuals are disclosed in Table 2; all blood donors originated from 
southern Peru, mostly from Arequipa. The majority of them were male, 
and no difference in age or gender was observed (Table 2). In addition, no 
relationship with factors associated with retroviral infection was detected 
(data not shown), except for three individuals who reported previous 
blood transfusion (two persons) and tattooing (one person). Regarding 
other blood-transmitted diseases, HTLV co-positives with hepatitis B and 
syphilis were detected: antibody to hepatitis B core antigen (anti-HBc) 
was detected in four sera, hepatitis B surface antigen (HBsAg) in one 
serum, and rapid plasma reagin (RPR anti-T. pallidum) in another serum. 
No sera were HIV/HTLV co-infected.
diSCuSSioN
Seroepidemiological studies in native South American showed 
HTLV-1 and HTLV-2 carrier state: HTLV-1 foci in groups of Andean 
highlands of Colombia, Peru, Bolivia, Argentina and Chile, and HTLV-2 
in natives of the lowlands of Brazil, Paraguay and Chile7,13,22.
Although Peru harbors four different ethnic groups: the Quechuas of 
Inca origin, Nikkei of Japanese descent, Mestizo of mixed white-Indian, 
and blacks or mulattos of African origin, HTLV-1 has been detected in 
all groups, and a molecular clock study confirmed a post-Columbian 
introduction of virus in the country27.
The absence of HTLV-2 positive sera and HIV/HTLV co-infection 
in the present study could be explained by the rules of Peruvian blood 
banks, which exclude patients with STDs, MSM, and individuals who have 
been in prison during the last six months. Indeed, these results could be 
a consequence of community isolation and the uncommon injection drug 
use (IDU) in the country11, where the latter is thought to be the major route 
of HTLV-2 transmission in urban populations. In contrast to Brazil, where 
HTLV-2 is endemic among Amerindians and IDU2,4,5,13,21,22,23,25, HTLV-2 has 
only been detected in Peru in two Amazonian Indians and in MSM from 
cities near the Amazon19,28. Interestingly, only 11 (0.4%) out of 2,732 sera 
were HIV positive, none of which were co-infected with HTLV. 
Regarding the sensitivity and specificity of the HTLV screening kits 
employed in the present study, six out of nine indeterminate sera by WB 
were HTLV antibody negative on the ELISA screening kit that contains 
only HTLV-1 and HTLV-2 recombinant antigens (Biokit), suggesting 
that this kit is more specific for HTLV-1/2 antibody detection than the 
Vironostika kit. We could not, however, exclude HTLV seroconversion, 
and we recommend following-up of such individuals. Although the 
HGIP WB profile has been described in sera from individuals of tropical 
countries where malaria is endemic and does not denote true HTLV 
infection18, we recently described this WB profile in an individual during 
HTLV-seroconversion15. In addition, we described an inability to detect 
all HTLV-seroreactive samples (mostly HTLV-2 infected) when only one 
ELISA is employed for screening in high-risk populations from São Paulo, 
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table 1
Results obtained by screening and confirmatory tests for HTLV-1 and HTLV-2 infections in blood donors from Arequipa, Peru 
Sample code ELISA* Vironostika® ELISA** Vironostika® ELISA** Biokit WB pattern** WB 2.4
4 + + - Indet. p24
5 + + + HTLV-1
6 + + + HTLV-1
7 + + + HTLV-1
8 + + + HTLV-1
9 + + + HTLV-1
10 + + + HTLV-1
11 + + + Indet.p19, p24, p26, p28, p36, gp46-I
12 + + + Indet. (HGIP)
13 + + + HTLV-1
14 + + + HTLV-1
15 + + + HTLV-1
16 + + + HTLV-1
17 + + + HTLV-1
18 + + + HTLV-1
19 + + - Indet. (HGIP)
20 + + + HTLV-1
21 + + + Indet. p19
22 + + + HTLV-1
23 + + + HTLV-1
24 + + + HTLV-1
25 + + + HTLV-1
26 + + + HTLV-1
27 + + - Indet. p24, p28
28 + + - Indet. p19
29 + + + HTLV-1
30 + + + HTLV-1
31 + + + HTLV-1
32 + + - Indet. (HGIP)
33 + + + HTLV-1
34 + + + HTLV
35 + + + HTLV-1
36 + + + HTLV-1
37 + + - Indet. p24, p28
38 + + + HTLV-1
*Assay conducted in Arequipa; ** Assays conducted in Brazil. + denote reactive sera, - denote non-reactive sera, according to Materials and Methods. Indet: HTLV-
Indeterminate, HGIP: HTLV-1 gag indeterminate pattern (p19, p26, p28, p32, p36). Enzyme-linked immunosorbent assays: Vironostika HTLV-I/II, BioMerieux, 
France, and BioELISA HTLV-I+II (r) (BioKit S.A., Spain). Western Blot assay: WB 2.4, Genelabs, Singapore. 
Brazil5,6,14,15, and suggested the use of two ELISAs of different compounds 
and formats for screening in this country (contrary to the recommendation 
of the Ministry of Health of Brazil)16. The same strategy has been conducted 
in Argentina, where the combination of two HTLV screening assays was 
shown to be useful for blood banks3. The significance of the indeterminate 
profile (by WB) in sera from blood donors of Arequipa is unknown, but 
malaria should be excluded since this is not an endemic area. Unfortunately, 
this work was limited by its cross-sectional design, and follow-up of such 
individuals was not done. More studies are in progress in order to confirm 
the Biokit ELISA as the most appropriate for screening in regions were 
HTLV-1 and HTLV-2 are endemic. 
Aside from clinical diagnosis, HTLV-1/2 confirmatory tests were not 
mandatory in Peruvian blood banks making it impossible to know the 
actual prevalence of such viruses among blood donors and to compare 
the results.
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The huge number of HTLV-1-infected men among blood donors 
could be a consequence of the high number of donors of this gender. An 
age-and-gender-cohort effect due to the characteristics of blood donors 
worldwide could not be excluded.
Finally, the main result that emerges from this study is the high 
prevalence of HTLV-1 among individuals without behavioral risk factors 
for acquiring retroviruses, which confirms Arequipa as an endemic region 
of HTLV-1. The correct diagnosis of HTLV-1 is important for prompt 
attention and counseling these individuals to avoid vertical and sexual virus 
transmission. Indeed, the results obtained suggest that HTLV-2 has probably 
not yet been introduced in healthy persons from southern Peru. 
reSuMo
Confirmação da presença de infecção por htlV-1 e ausência de 
infecção por htlV-2 em doadores de sangue de arequipa, peru
Estudos epidemiológicos conduzidos no Peru apontam a infecção 
por HTLV-1 como prevalente em diferentes grupos étnicos e por 
table 2
Demographic characteristics of HTLV-1/2-seropositive individuals (n = 35)




Gender (n) Female 8
Male 27
Origin (n) Arequipa 27
Puno 5
Cuzco 3
N = number of individuals.
Fig. 1 - Patterns of HTLV-reactivity obtained from serum samples of blood donors from 
Arequipa, Peru using WB 2.4 (Genelabs, Singapore). Lanes 1, 2 and 3 denote HTLV-1, 
HTLV-2 and HTLV-negative controls; Lanes 4 to 28 correspond to serum samples from 
blood donors. 
HTLV-2 restrita a alguns índios da região Amazônica e a homens que 
fazem sexo com homens. Não existem dados sobre a infecção por 
HTLV-1/2 em doadores de sangue de Arequipa, região montanhosa 
do sul do Peru. Portanto, o presente estudo pesquisou anticorpos 
anti-HTLV-1 e HTLV-2 em 2.732 doadores de sangue desta região 
geográfica. Foram utilizados na triagem sorológica os testes 
imunoenzimáticos (ELISA) e para confirmação dos resultados o 
Western Blot (WB). Soros reagentes no ELISA tiveram suas bolsas de 
sangue descartadas. Os resultados obtidos foram analisados de acordo 
com características demográficas dos indivíduos. Trinta e cinco soros 
(1,2%) resultaram HTLV-1/2 reagentes no ELISA, 25 confirmaram 
infecção por HTLV-1 no WB. Um soro resultou HTLV positivo e os 
nove soros restantes resultaram em padrão indeterminado no WB: 
três com perfil HTLV-1 Gag indeterminado. A média de idade dos 
indivíduos HTLV positivos foi de 34,6 anos; 27 do gênero masculino 
e oito do gênero feminino. Todos eram da região sul do país: 27 de 
Arequipa, cinco de Puno e três de Cuzco. Foi detectada co-positividade 
HTLV com hepatite B (cinco soros) e sífilis (um soro). Nenhum soro 
resultou positivo para a co-infecção HIV/HTLV. Havia dois indivíduos 
com transfusão prévia e um com tatuagem. Este trabalho confirma 
pela primeira vez infecção por HTLV-1 e ausência de infecção por 
HTLV-2 em doadores de sangue de Arequipa, sul do Peru e sugere que 
a transmissão vertical seja a principal via de transmissão/aquisição 
de HTLV-1 nesta região geográfica.
reFereNCeS
 1. ALARCóN, J.O.; FRIEDMAN, H.B.; MONTANO, S.M. et al. - High endemicity of 
human T-cell lymphotropic virus type I among pregnant women in Peru. j. acquir. 
immune defic. Syndr., 42: 604-609, 2006.
 2. ALCâNTARA, L.C.J.; SHINDO, N.; VAN DOOREN, S. et al. - Brazilian HTLV type 
2a strains from intravenous drug users (IDUs) appear to have originated from two 
sources: Brazilian Amerindians and European/North American IDUs. aidS res. 
hum. retrovir., 19: 519-523, 2003.
 3. BERINI, C.A.; PASCUCCIO, S.; BAUTISTA, C.T. et al. - Comparison of four commercial 
screening assays for the diagnosis of human T-cell lymphotropic virus types 1 and 
2. j. virol. meth., 147: 322-327, 2008.
 4. CASSEB, J.; CATERINO-DE-ARAUJO, A.; HONG, M.A. et al. - Prevalence of HTLV-I 
and HTLV-II infections among HIV-1-infected asymptomatic individuals in São Paulo, 
Brazil. rev. inst. Med. trop. S. paulo, 39: 213-215, 1997.
 5. CATERINO-DE-ARAUJO, A.; SANTOS-FORTUNA, E.; MELEIRO, M.C. et al. - 
Sensitivity of two ELISA tests in relation to Western blot in detecting HTLV-I and 
HTLV-II infections among HIV-1-infected patients from São Paulo, Brazil. diagn. 
Microbiol. infect. dis., 30: 173-182, 1998. 
 6. CATERINO-DE-ARAUJO, A.; CASSEB, J.S.R.; NEITzERT, E. et al. - HTLV-I and 
HTLV-II infections among HIV-1 seropositive patients in São Paulo, Brazil. europ. 
j. epidem., 10: 165-171, 1994.
 7. FUJIOSHI, T.; LI, H.C.; LOU, H. et al. - Characteristic distribution of HTLV type I and 
HTLV type II carriers among native ethnic groups in South America. aidS res. 
hum. retrovir., 15: 1235-1239, 1999.
 8. GOTUzzO, E.; CABRERA, J.; DEzA, L. et al. - Clinical characteristics of patients 
in Peru with human T cell lymphotropic virus type-1-associated tropical spastic 
paraparesis. Clin. infect. dis., 39: 939-944, 2004.
 9. GOTUzzO, E.; DE LAS CASAS, C.; DEzA, L. et al. - Tropical spastic paraparesis and 
HTLV-I infection: clinical and epidemiological study in Lima, Peru. j. neurol. Sci., 
143: 114-117, 1996.
QUISPE, N.C.S.; FERIA, E.B.; SANTOS-FORTUNA, E. & CATERINO-DE-ARAUJO, A. - Confirming the presence of HTLV-1 infection and the absence of HTLV-2 in blood donors from 
Arequipa, Peru. rev. inst. Med. trop. S. paulo, 51(1): 25-29, 2009.
29
 10. GOTUzzO, E.; MOODy, J.; VERDONCK, K. et al. - Frequent HTLV-1 infection in the 
offspring of Peruvian women with HTLV-1-associated myelopathy/tropical spastic 
paraparesis or strongyloidiasis. rev. panamer. Salud publ., 22: 223-230, 2007.
 11. GOTUzzO, E.; SANCHEz, J.; ESCAMILLA, J. et al. - Human T cell lymphotropic virus 
type I infection among female sex workers in Peru. j. infect. dis., 169: 754-759, 
1994.
 12. GOTUzzO, E. - Risk of transfusion-transmitted human T-cell lymphotropic virus-type 
I in Latin America. int. j. infect. dis., 4: 59-61, 2000.
 13. ISHAK, R.; VALLINOTO, A.C.R.; AzEVEDO, V.N. & ISHAK, M.O.G. -Epidemiological 
aspects of retrovirus (HTLV) infection among Indian populations in the Amazon 
region of Brazil. Cadern. Saúde publ. (rio de j.), 19: 101-114, 2003.
 14. JACOB, F.; SANTOS-FORTUNA, E.; AzEVEDO, R.S. & CATERINO-DE-ARAUJO, 
A. - Performances of HTLV serological tests in diagnosing HTLV infection in high-
risk population of São Paulo, Brazil. rev. inst. Med. trop. S. paulo, 49: 361-364, 
2007.
 15. JACOB, F.; SANTOS-FORTUNA, E.; AzEVEDO, R.S. & CATERINO-DE-ARAUJO, 
A. - Serological patterns and temporal trend of HTLV-1/2 infection in high-risk 
populations attending Public Health Units of São Paulo, Brazil. j. clin. Virol., 42: 
149-155, 2008.
 16. JACOB, F.; SANTOS-FORTUNA, E. & CATERINO-DE-ARAUJO, A. - Algoritmo de 
testes sorológicos de triagem para infecção por HTLV-1/2 usado no Instituto Adolfo 
Lutz de São Paulo. Bol. epidem. paul., 5(49), janeiro, 2008.
 17. LAGUNA-TORRES, V.A.; PéREz-BAO, J.; CHAUCA, G. et al. - Epidemiology of 
transfusion-transmitted infections among multi-transfused patients in seven hospitals 
in Peru. j. clin. Virol., 34 (suppl. 2): S61-68, 2005.
 18. MAHIEUx, R.; HORAL, P.; MAUCLèRE, P. et al. - Human T-cell lymphotropic virus 
type 1 gag indeterminate Western blot patterns in Central Africa: relationship to 
Plasmodium falciparum infection. j. clin. Microbiol., 38: 4049-4057, 2000.
 19. MEDEOT, S.; NATES, S.; RECALDE, A. et al. - Prevalence of antibody to human T cell 
lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina 
and the Amazon region of Peru. amer. j. trop. Med. hyg., 60: 623-629, 1999.
 20. MINISTERIO DEL SALUD DEL PERU - Da. Normas y procedimientos PRONAHRBAS 
Programa Nacional de Hemoterapia y Bancos de Sangre / Peru. Lima, Ministerio del 
Salud, 1998. (Decreto Supremo numero 002-92-AS).
 21. MORIMOTO, H.K.; CATERINO-DE-ARAUJO, A.; MORIMOTO, A.A. et al. - 
Seroprevalence and risk factors for human T-cell lymphotropic virus type 1 and 2 
infection in human immunodeficiency virus (HIV)-infected patients attending AIDS 
referral center health units in Londrina and other communities in Paraná, Brazil. 
aidS res. hum. retrovir., 21: 256-262, 2005.
 22. ROUCOUx, D.F. & MURPHy, E.L. - The epidemiology and disease outcomes of human 
T-lymphotropic virus type II. aidS rev., 6: 144-154, 2004.
 23. SALEMI, M.; LEWIS, M.; EGAN, J.F. et al. - Different population dynamics of human T 
cell lymphotropic virus type II in intravenous drug users compared with endemically 
infected tribes. proc. nat. acad. Sci. (wash.), 96: 13253-13258, 1999.
 24. SANCHEz-PALACIOS, C.; GOTUzzO, E.; VANDAMME, A.M. & MALDONADO, 
y. - Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) 
infection among ethnically and geographically diverse Peruvian women. int. j. infect. 
dis., 7: 132-137, 2003.
 25. SHINDO, N.; ALCâNTARA, L.C.J.; VAN DOOREN, S. et al. - Human retroviruses 
(HIV and HTLV) in Brazilian Indians: serological study and molecular epidemiology 
of HTLV type 2 isolates. aidS res. hum. retrovir., 18: 71-77, 2002.
 26. TRUJILLO, L.; MUñOz, D.; GOTUzzO, E.; yI, A. & WATTS, D.M. - Sexual practices 
and prevalence of HIV, HTLV-I/II, and Treponema pallidum among clandestine female 
sex workers in Lima, Peru. Sex. transm. dis., 26: 115-118, 1999.
 27. VAN DOOREN, S.; GOTUzzO, E.; SALEMI. M. et al. - Evidence for a post-Columbian 
introduction of human T-cell lymphotropic virus in Latin America. j. gen. Virol., 79: 
2695-2708, 1998.
 28. zUNT, J.R.; LA ROSA, A.M.; PEINADO, J. et al. - Risk factors for HTLV-II infection 
in Peruvian men who have sex with men. amer. j. trop. Med. hyg., 74: 922-925, 
2006.
 29. zURITA, S.; COSTA, C.; WATTS, D. et al. - Prevalence of human retroviral infection in 
Quillabamba and Cuzco, Peru: a new endemic area for human T cell lymphotropic 
virus type 1. amer. j. trop. Med. hyg., 56: 561-565, 1997.
Received: 12 February 2008
Accepted: 27 November 2008
